Grant Funding

United States, Canada

Continual advances in medical research help millions of people living with HIV have longer, more fulfilling lives today. But HIV continues to have a devastating impact, especially on people who belong to underserved communities and who lack access to medical care. Gilead supports organizations working to help individuals learn their status and get the care they need. We also support organizations that aim to solve the challenges of tomorrow, including how to:

• Understand the impact HIV has on an aging population
• Ensure continuity and retention in care
• Spark appreciation for innovative thinking in HIV treatment
• Identify and create a new generation of advocates

Gilead works to address the HIV epidemic by discovering transformative and life-saving medicines, developing simplified treatment regimens that increase efficacy, expanding access to treatment for those who need it most and building communities among people affected by HIV and AIDS. Continuing on this commitment, Gilead will partner with and support institutions, community groups and organizations that are engaged in HIV cure activities by providing grant funding.

More tools than ever are now available to help prevent HIV infection. Yet about 40,000 new cases of HIV are still reported in the U.S. each year. Gilead supports the efforts of community-based organizations, public health entities and similar nonprofit organizations to educate their constituents about comprehensive HIV prevention, including the role of pre-exposure prophylaxis (PrEP). Specifically, Gilead supports programs designed to:

• Provide comprehensive education on the range of prevention options and strategies available
• Ensure biomedical prevention plans, such as PrEP, are implemented safely and effectively in accordance with recommended guidelines
• Engage communities and individuals at highest risk for HIV infection in prevention efforts

Each year, more Americans die from Hepatitis C than HIV. Yet public awareness of this disease remains limited because of its disproportionate impact on drug users, minorities and other at-risk groups. Gilead is working to change this by funding organizations that raise awareness of the importance of testing and access to care among these groups, as well as those that:

• Look for ways to increase treatment capacity and sustainability
• Move individuals down the care pathway from screening to cure
• Eliminate intrinsic barriers to care and treatment

Cancer remains one of the greatest health challenges we face. While the search for a cure continues, education and awareness are powerful tools to support diagnosis and treatment. Gilead supports organizations focused on health equity in order to:

• Enable people affected by cancer and their caregivers to make informed health decisions
• Educate healthcare providers on identification, screening and diagnosis
• Improve access to prevention and treatment by overcoming barriers to care

From cystic fibrosis (CF) to influenza, inflammatory and respiratory diseases have a substantial impact on people of every age, gender, ethnic group and economic class. Gilead funds organizations that work in this therapeutic area to:

• Improve individuals’ health literacy, enabling them to make informed health decisions
• Educate healthcare providers on identification, screening and diagnosis
• Improve access to treatment by overcoming financial and other obstacles

Anguilla, Antigua and Barbuda, Argentina, Aruba, the Bahamas, Barbados, Belize, Bolivia, Brazil, British Virgin Islands, Cayman Islands, Chile, Colombia, Costa Rica, Cuba, Curacao, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Saint Maarten, St. Kitts and Nevis, St. Lucia, St. Vincent & The Grenadines, Suriname, Trinidad and Tobago, Turks and Caicos Islands, Uruguay, Venezuela

Gilead places a strong emphasis on combating the HIV epidemic in Latin America and the Caribbean. Despite advancements in medicines and treatments, HIV’s devastating and inequitable impact remains, particularly among indigenous people living in remote regions of Peru as well as young people throughout Latin America. In the Caribbean, more than 230,000 people are living with the disease, making the region’s HIV prevalence the second highest of anywhere in the world.

In other populous areas, the social stigma of HIV-positive status leads many to decline treatment or travel great distances to be treated outside their community. Elsewhere, poor treatment options for incarcerated populations (a group that faces systemic barriers to receiving quality HIV care) leads to public health concerns as individuals complete their rehabilitation programs and re-enter society.

Gilead supports organizations working to help individuals learn their status and get the care they need. We also fund groups looking to meet the unique needs of the region, including:

• Increasing awareness and understanding of HIV incidence and treatment methods
• Facilitating medicine provision and local provider expertise
• Supporting linkage to care programs
• Identifying and fostering prevention programs for at-risk individuals; for example, via pre-exposure prophylaxis (PrEP)

Treating Hepatitis B (HBV), Hepatitis C (HCV) and other forms of liver disease can be a challenge in Latin America and the Caribbean for a variety of reasons. One critical difficulty centers on reaching at-risk groups with screening and diagnosis. The estimated percentage of undiagnosed individuals living with HCV in Latin America and the Caribbean has gone unchanged over the span of many years. Lack of disease awareness and diagnosis options have contributed to the persistence of this gap. Even in areas where intravenous drug use and other behaviors that can increase risk are better understood, many hospital procedures are not performed in sterile conditions, with individuals contracting viral hepatitis in the process.

Our grantee partners seek to increase awareness of risk factors and the educational tools available to patient communities throughout the region. Gilead also funds projects to improve diagnostics and build medical specialization in HBV and HCV.

Gilead is working to improve the overall continuum of care for liver diseases by funding organizations that:

• Ensure providers have the training and expertise they need to deliver proper care
• Improve infrastructure and screening ability of regions where care is dependent on viral load
• Reduce undiagnosed totals
• Increase awareness of risk factors

Though priority is given to projects related to HIV- and liver disease-related projects, Gilead will consider grant proposals outside of these therapeutic areas, provided they conform to our eligibility restrictions. These proposals may include (but are not limited to):

• Access and education surrounding antifungal treatments
• Social services (homeless shelters, food banks, etc.)
• Community vibrancy projects (STEM education, arts support, community beautification, etc.)

United Kingdom, Austria, Benelux, Czech Republic, Denmark, France, Finland, Germany, Greece, Ireland, Italy, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Turkey

Our grantmaking in EMEA focuses on all of our core therapeutic areas:

• HIV
• Liver Disease
• Hematology & Oncology
• Inflammatory and Respiratory Diseases

Within these therapeutic areas, we provide support for a broad range of activities, including:

• Disease awareness
• Disease prevention
• Professional education
• Improving access to care
• Improving quality of care

Countries Supported: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic (CAR), Chad, Comoros, Democratic Republic of the Congo, Republic of the Congo, Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome & Pr., Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe

Our grantmaking in Africa focuses on the following therapeutic areas:

• HIV/AIDS
• Viral Hepatitis

Within these therapeutic areas, we provide support for a broad range of activities, including:

• Disease awareness
• Disease prevention
• Professional education
• Improving patient access to care
• Improving quality of care
• Increasing scientific capacity
• Strengthening healthcare systems

Afghanistan, Bangladesh, Bhutan, Cambodia, China, Fiji, Hong Kong, India, Indonesia, Kiribati, Kyrgyz Republic, Lao PDR, Malaysia, Maldives, Mongolia, Myanmar, Nauru, Nepal, Pakistan, Palau, Papua New Guinea, Philippines, Samoa, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Tajikistan, Thailand, Timor-Leste, Tonga, Turkmenistan, Truvalu, Uzbekistan, Vanuatu, Vietnam.

Our grantmaking in Asia focuses on the following therapeutic areas:

• HIV/AIDS
• Oncology
• Viral Hepatitis

Within these therapeutic areas, we provide support for a broad range of activities, including:

• Disease awareness
• Disease prevention
• Professional education
• Improving patient access to care
• Improving quality of care
• Increasing scientific capacity
• Strengthening healthcare systems